

1 **Clinical Characteristics and Factors Associated with Long COVID in Zambia, August 2020 to January**  
2 **2023: A Mixed Methods Design**

3 Warren Malambo<sup>1\*</sup>, Duncan Chanda<sup>2,3</sup>, Lily Besa<sup>3</sup>, Daniella Engamba<sup>2,3</sup>, Linos Mwiinga<sup>1</sup>, Mundia  
4 Mwitumwa<sup>2</sup>, Peter Matibula<sup>2</sup>, Neil Naik<sup>2</sup>, Suilanji Sivile<sup>2,3</sup>, Simon Agolory<sup>1</sup>, Andrew Auld<sup>1</sup>, Lloyd  
5 Mulenga<sup>3</sup>, Jonas Z. Hines<sup>1,¶</sup>, Sombo Fwoloshi<sup>2,3, ¶</sup>

6 <sup>1</sup> U.S. Centers for Disease Control and Prevention, Division of Global HIV/TB, Lusaka, Zambia

7 <sup>2</sup> University Teaching Hospital Adult and Emergency Hospital, Department of Internal Medicine,  
8 Lusaka, Zambia

9 <sup>3</sup> Ministry of Health, Lusaka, Zambia

10

11

12 \* Corresponding author:

13 Email: [ykh1@cdc.gov](mailto:ykh1@cdc.gov) (WM)

14

15 <sup>¶</sup> These authors contributed equally to this work.

16

17

## 18 **Abstract**

### 19 **Introduction**

20 A number of seroprevalence studies in Zambia document the extent of spread of SARS-CoV-2, yet  
21 few have examined signs, symptoms and conditions that continue or develop after acute COVID-19  
22 infection (long COVID). This is an important gap given the estimated prevalence of long COVID in  
23 other countries. We sought to examine characteristics of post-acute COVID-19 (PAC-19) clinics  
24 patients in Zambia and assess factors associated with long COVID at first visit to a PAC-19 clinic and  
25 longitudinally among a cohort of patients.

### 26 **Methods**

27 Long COVID was defined, initially in the Zambia PAC-19 clinical guidelines, as new, relapsing, or  
28 persistent symptoms lasting >4 weeks after an initial SARS-CoV-2 infection. Severe COVID-19 was  
29 defined as COVID-19 episode that required supplemental oxygen therapy, intensive care unit stay or  
30 treatment with steroids/remdesivir. We performed a cross-sectional and longitudinal analysis of  
31 PAC-19 clinic patients from August 2020 to January 2023 using logistic and mixed effects regression  
32 models and considered statistical significance at  $p < 0.05$ .

### 33 **Results**

34 In total, 1,359 patients attended PAC-19 clinics of whom 548 (40.3%) with  $\geq 2$  visits were included in  
35 the longitudinal analysis. Patients' median age was 53 (interquartile range [IQR]: 41-63) years, 919  
36 (67.6%) were hospitalized for acute COVID-19, and of whom 686 (74.6%) had severe COVID-19.  
37 Patients with hospital length of stay  $\geq 15$  days (adjusted odds ratio [aOR]: 5.37; 95% confidence  
38 interval [95% CI]: 2.99-10.0), severe illness (aOR: 3.22; 95% CI: 1.68-6.73), and comorbidities  
39 (aOR: 1.50; 95% CI: 1.02-2.21) had significantly higher likelihood of long COVID. Longitudinally, long  
40 COVID prevalence significantly ( $p < 0.001$ ) declined from 75.4% at the first PAC-19 visit to 26.0% by  
41 the fifth visit. The median follow-up time was 7 (IQR: 4-12) weeks.

### 42 **Conclusion**

43 Long COVID symptoms were common among patient presenting for care in PAC-19 clinics in Zambia,  
44 but most recovered within  $\sim 2$  months. Despite potentially substantial morbidity due to long COVID,  
45 few patients overall with COVID-19 attended a PAC-19 clinic. Scaling up PAC-19 services and  
46 integrating into routine clinical care could improve access by patients.

47

## 48 **Introduction**

49 Since the identification of the first SARS-CoV-2 infections in December 2019, the Coronavirus disease  
50 2019 (COVID-19) has become a major public health problem. Its morbidity and mortality dramatically  
51 increased across countries and regions leading to its classification as a pandemic [1]. As of February  
52 2024, the World Health Organization (WHO) had reported over 774 million cumulative COVID-19 cases  
53 and over 7 million cumulative COVID-19 deaths globally [2]. In the Africa region alone, over 9.5 million  
54 cumulative COVID-19 cases and over 175 thousand COVID-19 deaths were reported for the same time  
55 period.

56 People infected with SARS-CoV-2 commonly develop symptoms within 4-5 days following exposure  
57 although others may be asymptomatic [3]. Acute COVID-19 (within 4 weeks from the initial SARS-CoV-2  
58 infection) presents with as a multi-system cluster of symptoms, i.e., general, cardiovascular, pulmonary,  
59 gastrointestinal, neurologic, musculoskeletal, and ear, nose, and throat. Recovery from COVID-19 for  
60 most patients occurs within 7-10 days after symptoms onset but could take weeks to months in some  
61 patients [4-7]. Previous epidemics such the 2003 severe acute respiratory syndrome (SARS) and the  
62 2012 Saudi Arabia Middle East respiratory syndrome coronavirus (MERS-CoV) had patients who  
63 presented with persistent symptoms post-acute infection [8-11]. Their symptoms included fatigue,  
64 decreased quality of life, shortness of breath and behavior health problems that impacted on their  
65 health-related quality of life.

66 Symptoms and conditions that continue or develop after acute COVID-19 infection are variably named  
67 (post-acute COVID-19, post-acute sequelae of SARS-CoV-2 infection, post-COVID conditions, long-haul  
68 COVID, post-COVID conditions, long-term effects of COVID and chronic COVID) but are also referred to  
69 as long COVID [6, 12]. Commonly reported long COVID symptoms include fatigue, fever, cough,  
70 dizziness, brain fog, and myalgia although symptoms are varied and potentially have overlapping  
71 etiologies [13-15]. Long COVID is thus a syndrome characterized by persistent, new, relapsing or  
72 delayed SAR-CoV-2 symptoms  $\geq 12$  weeks beyond onset of the acute episode [12, 16-18], and can have a  
73 protracted path to recovery that impacts on quality of life, earnings and health care costs [19-21].

74 As much as 77 million people around the world could be estimated to have long COVID, based on a  
75 conservative estimated prevalence of 10% of reported number of infected people [2, 22]; the actual  
76 number may likely be much higher given undocumented cases due to limited testing capacity. Among  
77 acute-COVID-19 outpatient cases, the prevalence of long COVID is estimated at 10-30%; 50-70% of  
78 hospitalized cases and 10-12% of vaccinated cases [22-27]. For example, a study of the burden,

79 causation, and particularities of long COVID in 7 African countries estimated a pooled long COVID  
80 prevalence of 41% [28]. Long COVID is associated with increasing age, comorbidities, hospitalization for  
81 acute COVID-19, severe COVID-19, and vaccination status [29-31]. Vaccination against SARS-CoV-2 is,  
82 however, associated with reduced likelihood of severe COVID-19 and long COVID.

83 There's growing evidence on long COVID from countries in Africa [28, 32-34]. Disease severity and  
84 admission to the intensive care unit during acute COVID-19, for example, were found to be associated  
85 with long COVID in Nigeria and South Africa [35, 36]. Scoping studies on long COVID in Africa found  
86 comorbidities and age >40 years to be associated factors [33, 37]. In Zambia, 17% of persons with acute  
87 COVID-19 in July 2020 were found to be experiencing symptoms ~2 months later [38]. Zambia's reported  
88 COVID-19 cases are, however, likely an underestimate given limited testing capacity, asymptomatic  
89 infections, and mild clinically ill cases who may not have come to the attention of the health system [39-  
90 41].

91 While a number of seroprevalence studies in Zambia document the extent of spread of SARS-CoV-2, few  
92 have examined longer term outcomes such as long COVID [36, 39, 41-45]. This is an important gap given  
93 the estimated prevalence of long COVID and extent of SARS-CoV-2 transmission in other countries in  
94 Africa. In this study, we examined the characteristics of patients presenting for care in specialized post-  
95 acute COVID-19 (PAC-19) clinics in Zambia and assessed factors associated with long COVID at first visit  
96 to a PAC-19 clinic and longitudinally among a cohort of patients with  $\geq 2$  PAC-19 clinic visits.

## 97 **Methods**

### 98 **Study setting**

99 Beginning August 2020, the Zambia Ministry of Health set up 13 specialized PAC-19 clinics to care for  
100 people following SARS-CoV-2 infection, initially at the two national referral hospitals in Lusaka city, the  
101 capital of Zambia, and subsequently at 11 other major hospitals across all 10 provinces of Zambia.

### 102 **Study participants**

103 Per national PAC-19 clinical guidelines, patients diagnosed with SARS-CoV-2 infection presented in PAC-  
104 19 clinics for follow-up care after discharge from hospital admission or outpatient episodic [46]. At the  
105 first PAC-19 clinic visit, patients' demographics, medical history, comorbidities, and current symptoms  
106 were recorded on a standardized paper form. Physical examinations and laboratory investigations were  
107 conducted based on patient's medical history as required. Patients' ability to perform activities, as part  
108 of examination of their functional and mental health status, were also evaluated.

109 Further clinical appointments of up to 5 review visits were at the clinicians' discretion. Symptoms were  
110 assessed by clinicians at each PAC-19 clinic visit on review of systems: general, cardiovascular,  
111 pulmonary, urinary, neurologic, musculoskeletal, ear, nose, and throat (ENT), mental health concerns,  
112 depression, anxiety, and dermatologic. Pre-existing comorbidities (hypertension, diabetes,  
113 cardiovascular disease, cancer, chronic lung disease, kidney disease, or liver disease,  
114 immunosuppression, obesity, HIV and TB) were documented. Patients requiring further specialist care  
115 were referred to various units including physiotherapy, cardiology, endocrinology, nephrology,  
116 psychiatry, and pulmonology. Anonymized data from patients standardized clinical paper forms were  
117 routinely abstracted into an electronic database (REDCap v11.0.3); which was accessed on 5<sup>th</sup> January  
118 2023 and analyzed for this study.

### 119 **Study design**

120 We implemented a mixed methods design to assess for factors associated with long COVID at first visit  
121 to a PAC-19 clinic and longitudinally across review visits. First, we performed a cross-sectional analysis of  
122 all PAC-19 clinic patients with data entered in the REDCap electronic databases from August 5, 2020,  
123 through to January 26, 2023. We then did a longitudinal sub-analysis of patients with  $\geq 2$  PAC-19 clinic  
124 review visits.

125 The longitudinal sub-analysis data structure included repeated observations of long COVID symptoms  
126 and patient-level characteristics. Demographic and clinical characteristics of patients included time-  
127 invariant covariates sex, age (patients repeatedly observed for  $< 1$  year), presence of newly diagnosed  
128 medical conditions, presence of pre-existing comorbidities, and acute COVID-19 episode details. Time-  
129 variant covariates included COVID-19 vaccination status and referral to specialist services.

### 130 **Study variables and definitions**

131 Long COVID was defined, initially in the Zambia post-acute COVID-19 guidelines, as new, relapsing or  
132 persistent COVID-19 symptoms that lasted greater than 4 weeks after the initial SARS-CoV-2 infection  
133 [46, 47]. Severe COVID-19 was defined as COVID-19 episode that required supplemental oxygen  
134 therapy, intensive care unit (ICU) stay or treatment with steroids or remdesivir. Vaccination status  
135 categorization was based on vaccination records, when available, or patients' self-reported status. SARS  
136 CoV-2 variants classification was based on the dominant variant at the time of SARS-CoV-2 diagnosis as  
137 captured by the Zambia's genomic surveillance system and submitted to the Global Initiative on Sharing  
138 All Influenza Data (GISAID) rather than sequenced specimens from patients [48]. Diabetes, hypertension,

139 or deep vein thrombosis/pulmonary embolism detected at the time of SARS-CoV-2 diagnosis were  
140 categorized as newly diagnosed medical conditions.

#### 141 **Study size**

142 For the study sample size, we assumed prevalence of long COVID at 30% and a precision corresponding  
143 to the effect size of 5%. The prevalence or Cochrane formula (described elsewhere) was used to  
144 calculate the minimum sample size of 323 [49]. Study participants were included in the study if they  
145 were COVID-19 patients presenting in PAC-19 clinics for follow-up care after discharge from hospital or  
146 outpatient episodic care and had their information abstracted to the clinics' REDCap electronic  
147 database. A full enumeration of all PAC-19 clinic attendees was however considered for higher accuracy  
148 and precision. For the longitudinal sub-analysis, patients were excluded from the analysis if they  
149 attended a PAC-19 clinic only once.

#### 150 **Statistical Analysis**

151 At descriptive statistics we reported frequencies with proportions for categorical variables and medians  
152 with the interquartile range (IQR) for non-normally distributed numeric variables assessed using the  
153 Shapiro-Wilk test. The Pearson Chi-square and Kruskal Wallis tests for proportions and Wilcoxon rank  
154 sum test for medians were used to estimate the direction and magnitude of association. An unadjusted  
155 and adjusted logistic regression model was fitted to assess for factors associated with having long COVID  
156 at first visit to a PAC-19 clinic.

157 The main cross-sectional analysis was for patients hospitalized during acute COVID-19 (inpatients) to  
158 maintain key variables in the analysis. At multivariable analysis, we adjusted for age, presence of newly  
159 diagnosed medical conditions, presence of pre-existing comorbidities, and COVID-19 episode details  
160 (i.e., hospital length of stay, and presence of severe COVID-19). Covariate inclusion criteria at  
161 multivariable analysis were based on theoretical relevance to the study and statistical significance ( $p$ -  
162 value $\leq 0.2$ ). We also conducted an additional cross-sectional analysis that included both inpatients and  
163 outpatients during acute infection to assess for association of hospitalization during acute COVID-19  
164 with long COVID.

165 For the longitudinal sub-analysis, we fitted a mixed effects model to account for the heterogeneity in  
166 long COVID i.e., the differences between patients and within patients across repeated observations or  
167 PAC-19 clinic visits. An unadjusted and adjusted mixed effects model was separately fitted for acute  
168 COVID-19 inpatients only and additionally for both inpatients and outpatients. The patient was the  
169 random effects term for the model. Since there was dependence in the data, we also reported the

170 conditional intraclass correlation (ICC) which quantified the variance in long COVID heterogeneity that  
171 was attributable to between patients and within patients across PAC-19 visits.


172 Only covariates with <10% missingness were included at multivariable analyses. To assess for bias, we  
173 checked for the proportion of listwise deletion when covariates of interest with >10% missingness were  
174 included at multivariable analysis. Model selection was based on goodness-of-fit statistics (i.e., adjusted  
175 pseudo R<sup>2</sup>, Akaike information criteria, Bayesian information criteria and log-likelihood value). Analysis  
176 was done in R software version 4.3.2 (R Foundation for Statistical Computing) and statistical significance  
177 was considered at p<0.05.

### 178 **Ethical considerations**

179 This study was preconceived during the development of clinical and operational guidelines for the  
180 management of PAC-19 patients in Zambia. The study obtained ethical clearance (waiver for informed  
181 consent) from the University of Zambia Biomedical Research Ethics Committee (Ref No. 2711-2022),  
182 approval from the Zambia National Health Research Authority (Ref No: NHRA0002/26/05/2022) and was  
183 determined to be non-research according to the U.S Centers for Disease Control and Prevention (CDC)  
184 policy and applicable federal law (See e.g., 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C.  
185 §241(d); 5 U.S.C. 552a; 44 U.S.C.3501 et seq.). CDC investigators did not interact with patients or have  
186 access to personally identifiable information but participated in protocol development and analysis of  
187 anonymized data.

### 188 **Results**

189 In total, 1,359 patients that attended PAC-19 clinics from August 2020 to January 2023 were in the cross  
190 sectional analysis (Fig 1). Of these patients, 548 (40.3%) patients that had ≥2 PAC-19 clinic visits were  
191 included in the longitudinal sub-analysis. Most patients (919/1,087, 84.5%) were hospitalized during  
192 acute COVID-19 (Table 1). Overall, patients' median age was 53 (IQR: 41-63) years, and 693 (52.9%) were  
193 female. Most patients (58.0%) were from Lusaka, where the first two PAC-19 clinics were initially set up.  
194 Nearly half of the patients (46.9%) were diagnosed with COVID-19 when delta was the dominant variant  
195 (Fig. 2). The median time since COVID-19 diagnosis when patients presented for care in PAC-19 clinics  
196 was 4 (IQR:2-6) weeks.



197

198 **Fig 1:** Analysis flow diagram of PAC-19 clinic patients in Zambia, August 2020 – January 2023

199

200 **Table 1:** Demographic and Clinical Characteristics of Patients who Presented for Care in PAC-19 Clinics in  
201 Zambia, Aug. 2020–Jan. 2023

Characteristic	Presence of long COVID symptoms			p-value <sup>a</sup>
	Yes (377) n (%)	No (982) n (%)	Overall (1,359) n (%)	
<b>Sex</b>				0.994
Female	197 (53.0)	496 (52.9)	693 (52.9)	
Male	175 (47.0)	441 (47.1)	616 (47.1)	
(Missing)	5	45	50	
<b>Age (years)</b>				<b>0.016</b>
Median (IQR)	53 (43, 66)	52 (40, 63)	53 (41, 63)	
(Missing)	0	45	45	
<b>Age group (years)</b>				<b>0.039</b>
≤29	22 (5.8)	98 (10.5)	120 (9.1)	
30-39	47 (12.5)	132 (14.1)	179 (13.6)	
40-49	84 (22.3)	188 (20.1)	272 (20.7)	
50-59	82 (21.8)	219 (23.4)	301 (22.9)	
60+	142 (37.7)	300 (32.0)	442 (33.6)	
(Missing)	0	45	45	
<b>PAC-19 Clinic location</b>				0.152
Lusaka city	158 (54.5)	433 (59.4)	591 (58.0)	



Characteristic	Presence of long COVID symptoms			p-value <sup>a</sup>
	Yes (377) n (%)	No (982) n (%)	Overall (1,359) n (%)	
Other districts (Missing)	132 (45.5) 87	296 (40.6) 253	428 (42.0) 340	
<b>Dominant SARS-CoV-2 variant at diagnosis <sup>b</sup></b>				<b>&lt;0.001</b>
Wild type	17 (4.6)	55 (5.8)	72 (5.4)	
Beta	94 (25.3)	186 (19.5)	280 (21.1)	
Delta	190 (51.1)	433 (45.3)	623 (46.9)	
Omicron	71 (19.1)	282 (29.5)	353 (26.6)	
(Missing)	5	26	31	
<b>Time since COVID-19 diagnosis (weeks) <sup>c</sup></b>				<b>&lt;0.001</b>
Median (IQR)	6 (5, 10)	3.0 (2, 5)	4.0 (2, 6)	
(Missing)	118	251	369	
<b>Presence of pre-existing comorbidities <sup>d</sup></b>				<b>&lt;0.001</b>
No	155 (41.1)	550 (56.0)	705 (51.9)	
Yes	222 (58.9)	432 (44.0)	654 (48.1)	
<b>Presence of newly diagnosed medical conditions <sup>e</sup></b>				<b>0.005</b>
No	331 (87.8)	909 (92.6)	1,240 (91.2)	
Yes	46 (12.2)	73 (7.4)	119 (8.8)	
<b>Vaccination status</b>				0.422
Not vaccinated	250 (78.1)	543 (75.8)	793 (76.5)	
Vaccinated	70 (21.9)	173 (24.2)	243 (23.5)	
(Missing)	57	266	323	
<b>Hospitalization status during acute COVID-19</b>				0.428
Outpatient	45 (14.1)	123 (16.0)	168 (15.5)	
Inpatient	274 (85.9)	645 (84.0)	919 (84.5)	
(Missing)	58	214	272	
<b>Hospitalization length of stay (days) <sup>f</sup></b>				<b>&lt;0.001</b>
1-3	19 (9.4)	139 (26.8)	158 (21.9)	
4-7	38 (18.8)	165 (31.8)	203 (28.2)	
8-14	48 (23.8)	125 (24.1)	173 (24.0)	
≥15	97 (48.0)	90 (17.3)	187 (25.9)	
(Missing)	72	126	198	
<b>Severe COVID <sup>f, g</sup></b>				<b>0.001</b>
No	50 (18.2)	183 (28.4)	233 (25.4)	
Yes	224 (81.8)	462 (71.6)	686 (74.6)	
<b>Functional status since COVID-19</b>				<b>&lt;0.001</b>
Better	144 (55.2)	427 (78.8)	571 (71.1)	
Same/worse <sup>h</sup>	117 (44.8)	115 (21.2)	232 (28.9)	
(Missing)	116	440	556	
<b>Referral to specialist services <sup>i</sup></b>				<b>0.001</b>
No	221 (89.1)	614 (95.0)	835 (93.4)	
Yes	27 (10.9)	32 (5.0)	59 (6.6)	
(Missing)	129	336	465	

<sup>a</sup> Pearson Chi-square and Kruskal Wallis tests were used for proportions and Wilcoxon rank sum test for medians. Bolded p-values are significant at p<0.05

<sup>b</sup> SARS CoV-2 variants classification based on GISAID (2023) rather than sequenced specimens from study patients

<sup>c</sup> Computed as a difference in weeks between date of diagnosis and date of presentation at PAC-19 clinic

<sup>d</sup> Pre-existing comorbidity: hypertension, diabetes, cardiovascular disease, cancer, immunosuppression, chronic lung, kidney, and liver diseases, obesity, HIV and TB.

<sup>e</sup> Comorbidities (hypertension, diabetes, and HIV) diagnosed at the time of SARS CoV-2 infection.

<sup>f</sup> Denominator is 919 (i.e., patients hospitalized for acute COVID-19)


<sup>g</sup> Acute COVID-19 episode that required supplemental oxygen therapy, intensive care unit stay or treatment with steroids or remdesivir

<sup>h</sup> Same or worse limitations in daily activities since acute COVID-19

<sup>i</sup> Specialist services included physiotherapy, cardiology, endocrinology, nephrology, psychiatry, and pulmonology

202

203



204

205 **Fig 2:** PAC-19 clinic patients' attendance by date of diagnosis, August 2020 – January 2023

206

207 At baseline, 654 (48.1%) patients overall, reported having had pre-existing comorbidity. Among these  
 208 patients, hypertension (n=465, 71.1%), diabetes (n=172, 26.3%), HIV (n=165, 25.2%) and cardiovascular  
 209 disease (n=73, 11.2%) were commonly (frequency of  $\geq 10\%$ ) reported (S1 Table). One hundred nineteen  
 210 (8.8%) patients had been diagnosed with new medical conditions at the time of SARS-CoV-2 diagnosis.  
 211 Of these patients, hypertension and diabetes were detected at SARS-CoV-2 diagnosis in 68 (53.8%) and  
 212 64 (53.8%) patients, respectively.

213 Among the hospitalized acute COVID-19 patients, the median length of stay was 7 days (IQR:4-15 days).  
 214 Of these inpatients, 686 (74.6%) were categorized as having had severe COVID-19. The medium time  
 215 from the date of COVID-19 diagnosis to when patients presented for care in a PAC-19 clinic was 4 weeks  
 216 (IQR: 2-6 weeks). At first visit to a PAC-19 clinic, 274 (29.8%) hospitalized patients had long COVID.  
 217 Among these long COVID patients, commonly reported symptoms included cough (38.7%), fatigue  
 218 (38.5%), shortness of breath (26.5%), chest pain (20.9%), headache (14.8%), muscles aches/pain (14.1%),  
 219 palpitations (12.5%), joint aches/pain (11.9%), and forgetfulness or brain fog (8.0%). Among the  
 220 outpatients, 103 (23.4%) had long COVID, bringing the overall number of long COVID patients to 377  
 221 (27.7%).

222 Of all patients, 232 (28.9%) patients had worse or same (limitations in daily activities) functional status  
 223 since acute COVID-19. The functional status patients commonly reported difficulty in undertaking was  
 224 walking long distances greater than 1km (22.6%), day-to-day work/school (cognitive) activities (19.4%),  
 225 standing for ≥30 minutes (19.4%), taking care of household tasks (17.8%), and self-care (activities like  
 226 bathing and dressing) – 15.1%. Fifty-nine (6.6%) patients were referred to specialist care, including  
 227 cardiology (35.6%), endocrinology (33.9%), psychiatry (25.4%), pulmonology (18.6%), physiotherapy  
 228 (11.0%), and nephrology (1.7%).

229 Overall, 243 (23.5%) patients had been vaccinated before being diagnosed with SARS-CoV-2,  
 230 representing 28.5% of patients seen at PAC-19 clinics from April 2021 when COVID-19 vaccines first  
 231 became available in Zambia. Of these vaccinated patients, 102 (42%) received Johnson and Johnson’s  
 232 Janssen (Ad26.COV2.S), 97 (39.9%) received AstraZeneca (AZD1222), 41 (16.9%) did not know the  
 233 vaccine type they received, and 3 (1.2%) received Pfizer-BioNTech (BNT162b2). Fifty-seven (23.4%) had  
 234 received a full series of vaccines >14 days prior to their date of SARS-CoV-2 diagnosis, 31 (12.7%) were  
 235 partially vaccinated (i.e., 2nd dose not yet received), 10 (4.1%) were diagnosed with SARS-CoV-2 within  
 236 14 days of being vaccinations while 148 (60.9%) had missing vaccination dates to be classified.

237 Patients with pre-existing comorbidities (adjusted odds ratio [aOR]: 1.50; 95% confidence interval [CI]:  
 238 1.02-2.21), and with hospital length of stay of 8-14 and ≥15 days were associated with significantly  
 239 higher odds of long COVID (aOR: 1.98; CI: 95% 1.08-3.74, and aOR: 5.37; 95% CI: 2.99-10.0, respectively)  
 240 - Table 2. Patients who had severe COVID-19 had 3.23-fold (95% CI: 1.68-6.75) higher odds of presenting  
 241 with long COVID. Independently, vaccinated patients had non-significant reduced likelihood of long  
 242 COVID (OR: 0.94; 95% CI: 0.64-1.36) while those who were referred to specialist services had 1.88-fold  
 243 (95% CI: 1.00-3.48; p-value=0.045) increased likelihood of long COVID.

244 **Table 2:** Factors associated with long COVID at first visit to PAC-19 clinic among patients hospitalized for  
 245 acute COVID-19 in Zambia, August 2020 – January 2023 (N=919)

Variable	Unadjusted OR (95% CI)	p-value <sup>a</sup>	Adjusted OR (95% CI)	p-value <sup>a</sup>
<b>Sex</b>				
Female	<i>Referent</i>	-	<i>Referent</i>	-
Male	0.98 (0.74, 1.31)	0.912	0.92 (0.65-1.32)	0.667
<b>Age group (years)</b>				
≤29	<i>Referent</i>	-	<i>Referent</i>	-
30-39	1.73 (0.88, 3.51)	0.116	0.87 (0.38, 2.01)	0.741
40-49	2.01 (1.09, 3.87)	<b>0.029</b>	0.82 (0.39, 1.76)	0.596
50-59	1.69 (0.93, 3.24)	0.096	0.70 (0.33, 1.51)	0.350
60+	1.86 (1.05, 3.47)	<b>0.041</b>	0.61 (0.30, 1.28)	0.181

Variable	Unadjusted OR (95% CI)	p-value <sup>a</sup>	Adjusted OR (95% CI)	p-value <sup>a</sup>
<b>Presence of pre-existing comorbidities <sup>b</sup></b>				
No	<i>Referent</i>		<i>Referent</i>	-
Yes	1.50 (1.12, 2.01)	<b>0.006</b>	1.50 (1.02, 2.21)	<b>0.041</b>
<b>Presence of newly diagnosed medical conditions <sup>c</sup></b>				
No	<i>Referent</i>	-	<i>Referent</i>	-
Yes	1.48 (0.94, 2.30)	0.084	1.34 (0.78, 2.28)	0.284
<b>Hospital length of stay (days)</b>				
1-3	<i>Referent</i>	-	<i>Referent</i>	-
4-7	1.68 (0.94, 3.11)	0.086	1.26 (0.68, 2.39)	0.478
8-14	2.81 (1.59, 5.14)	<b>&lt;0.001</b>	1.98 (1.08, 3.74)	<b>0.031</b>
≥15	7.88 (4.60, 14.1)	<b>&lt;0.001</b>	5.37 (2.99, 10.0)	<b>&lt;0.001</b>
<b>Severe COVID-19 <sup>d</sup></b>				
No	<i>Referent</i>		<i>Referent</i>	-
Yes	1.77 (1.26, 2.54)	<b>0.001</b>	3.22 (1.68, 6.73)	<b>&lt;0.001</b>
<b>Vaccination status <sup>e</sup></b>				
Not vaccinated	<i>Referent</i>		-	-
Vaccinated	0.94 (0.64, 1.36)	0.737	-	-
<b>Referral to specialist services <sup>e</sup></b>				
No	<i>Referent</i>		-	-
Yes	1.88 (1.00, 3.48)	<b>0.045</b>	-	-

Abbreviation: OR - odds ratio; CI – confidence interval

<sup>a</sup> Bolded p-values are significant at p<0.05

<sup>b</sup> Pre-existing comorbidity: hypertension, diabetes, cardiovascular disease, cancer, immunosuppression, chronic lung, kidney, and liver diseases, obesity, HIV and TB.

<sup>c</sup> Comorbidities (hypertension, diabetes, and HIV) diagnosed at the time of SARS CoV-2 infection.

<sup>d</sup> Acute COVID-19 episode that required supplemental oxygen therapy, intensive care unit stay or treatment with steroids/ remdesivir

<sup>e</sup> Vaccination status and referral to specialist services were not adjusted for at multivariable analysis due to >10% missingness which resulted in 50.5% listwise deletion.

246  
247 In the additional cross-sectional analysis that included both inpatients and outpatients during acute  
248 COVID-19 (S2 Table), inpatients were associated with non-significant increased odds of long COVID (aOR:  
249 1.05; 95% CI: 0.72-1.55). Patients with the presence of comorbidities were, however, associated with  
250 significantly higher odds of long COVID (aOR: 1.55; 95% CI: 1.16-2.08) while the presence of newly  
251 diagnosed medical conditions had a non-significant increase likelihood of long COVID. Patients aged 40-  
252 49 years were significantly associated with 1.79-fold increased likelihood of long COVID (95% CI: 1.03-  
253 3.22). Independently, patients referred to specialist services were 2.34 times (95% CI: 1.37-4.00) more  
254 likely to present with long COVID. Males compared to females and having been vaccinated against  
255 COVID-19 were associated with non-significant reduced odds of long COVID.

256 In the longitudinal analysis (S1 Fig), the overall median time patients presented at a PAC-19 clinic was 7  
257 (IQR: 4-12) weeks. Longitudinally (Fig 3), the most frequently (≥5% at any PAC-19 clinic visit) reported

258 long COVID symptoms were cough (16.9%), fatigue (16.4%), shortness of breath (10.6%), chest pain  
 259 (8.4%), headache (8.3%), palpitations (6.6%) and muscle aches/pains (5.2%), and forgetfulness (3.0%).  
 260 The prevalence of long COVID significantly declined ( $p < 0.001$ ) from 75.4% at the first PAC-19 clinic visit  
 261 to 53.5% at the second visit, 59.8% at the third visit, 49.6% at the fourth visit, and 26.0% at the final visit  
 262 (S3 Table). Overall, the proportion of vaccinated patients attending PAC-19 clinics increased from 20% at  
 263 the first visit to 58% at the fifth visit; an increase that will statistically significant ( $p < 0.001$ ). Similarly,  
 264 comparatively significantly ( $p = 0.002$ ) larger proportion of patients with comorbidities presented in  
 265 subsequent PAC-19 clinic visits than at the first visit. The proportion of patients with newly diagnosed  
 266 medical conditions longitudinally declined; this was, however, non-significant ( $p = 0.953$ ).



267  
 268 **Fig 3:** Longitudinal frequency of most common long COVID symptoms by PAC-19 clinic visit, Aug. 2020 -  
 269 Jan. 2023

270  
 271 We found similar associations with long COVID in the longitudinal analysis (Table 3) as with the cross-  
 272 sectional analysis (Table 2). Across subsequent clinical visits, the odds of long COVID declined overall.  
 273 Patients with hospital length of stay of  $\geq 15$  days and those with severe COVID-19 had significantly  
 274 increased likelihood of presenting with long COVID (aOR: 4.30; 95% CI: 1.54-12.0, and aOR: 1.89; 95% CI:  
 275 1.02-3.49, respectively). Longitudinally, vaccinated patients had a non-significant reduced odds of long  
 276 COVID (aOR: 0.78; 95% CI: 0.45-1.35). Similarly, sex, age, presence of comorbidities and newly diagnosed  
 277 medical conditions were associated with non-significant likelihood of long COVID. For the longitudinal  
 278 model, the conditional ICC was estimated to be 0.562; suggesting that 56.2% of the longitudinal variance  
 279 in long COVID was attributable to between patient differences.

280  
 281

282 **Table 3:** Factors longitudinally association with long COVID among acute COVID-19 hospitalized patients in  
 283 Zambia, August 2020 – January 2023 (N=540)

Variable	Adjusted model <sup>a</sup>		Fully adjusted model <sup>b</sup>	
	aOR (95% CI)	p-value <sup>c</sup>	aOR (95% CI)	p-value <sup>c</sup>
<b>PAC-19 clinic visit</b>				
1	Referent	-	Referent	-
2	0.18 (0.12, 0.27)	<b>&lt;0.001</b>	0.18 (0.11, 0.31)	<b>&lt;0.001</b>
3	0.09 (0.04, 0.18)	<b>&lt;0.001</b>	0.09 (0.04, 0.21)	<b>&lt;0.001</b>
4	0.02 (0.01, 0.06)	<b>&lt;0.001</b>	0.02 (0.01, 0.06)	<b>&lt;0.001</b>
5	0.00 (0.00, 0.01)	<b>&lt;0.001</b>	0.00 (0.00, 0.02)	<b>&lt;0.001</b>
<b>Sex</b>				
Female	Referent	-	Referent	-
Male	0.81 (0.52, 1.27)	0.367	0.75 (0.42, 1.36)	0.348
<b>Age group (years)</b>				
≤29	Referent	-	Referent	-
30-39	2.25 (0.64, 7.94)	0.208	1.07 (0.19, 6.09)	0.937
40-49	1.60 (0.51, 5.02)	0.422	0.68 (0.14, 3.26)	0.634
50-59	1.56 (0.51, 4.81)	0.438	0.79 (0.17, 3.75)	0.765
60+	2.56 (0.85, 7.67)	0.094	1.27 (0.27, 5.84)	0.762
<b>Presence of newly diagnosed medical conditions</b>				
No	Referent	-	Referent	-
Yes	1.55 (0.76, 3.14)	0.227	1.41 (0.58, 3.43)	0.449
<b>Presence of comorbidities</b>				
No	Referent	-	Referent	-
Yes	1.86 (1.18, 2.92)	<b>0.007</b>	1.66 (0.88, 3.14)	0.117
<b>Hospital length of stay (days)</b>				
1-3	Referent	-	Referent	-
4-7	1.95 (0.72, 5.25)	0.187	1.73 (0.65, 4.61)	0.271
8-14	2.18 (0.80, 5.90)	0.127	1.74 (0.64, 4.71)	0.277
≥15	5.92 (2.14, 16.42)	<b>0.001</b>	4.30 (1.54, 12.0)	<b>0.005</b>
<b>Severe COVID-19 <sup>d</sup></b>				
No	Referent	-	Referent	-
Yes	1.44 (0.90, 2.31)	0.124	1.89 (1.02, 3.49)	<b>0.042</b>
<b>Vaccination status</b>				
Not vaccinated	Referent	-	Referent	-
Vaccinated	0.79 (0.50, 1.26)	0.326	0.78 (0.45, 1.35)	0.380
<b>Referral to specialist Services <sup>e</sup></b>				
No	Referent	-	-	-
Yes	1.01 (0.53, 1.95)	0.973	-	-
<b>Random Effects</b>				
Between PAC-19 clinic visit variance			3.29	
Within PAC-19 clinic visit variance			4.22	
Conditional intraclass correlation			0.56	

<sup>a</sup> Models adjusted for fixed effects term PAC-19 clinic visit occasion.

<sup>b</sup> Fully adjusted model included measurement occasion fixed effects term (PAC-19 clinic visit occasions) and patient level fixed effects terms: age (<29, 30-39, 40-49, 50-59, or +60 years), presence of comorbidities (yes or no), presence of newly diagnosed comorbidity (yes or no),

Variable	Adjusted model <sup>a</sup>		Fully adjusted model <sup>b</sup>	
	aOR (95% CI)	p-value <sup>c</sup>	aOR (95% CI)	p-value <sup>c</sup>
acute COVID-19 hospitalization length of stay (1-3, 4-7, 8-14, and ≥15 days), severe COVID-19 during acute COVID-19 (yes or no), and COVID-19 vaccination status (not vaccinated or vaccinated). The random-effects term for longitudinal clustering of repeated measure was the patient.				
<sup>c</sup> Bolded p-values are significant at p<0.05				
<sup>d</sup> Acute COVID-19 episode that required supplemental oxygen therapy, intensive care unit stay or treatment with steroids/remdesivir				
<sup>e</sup> Referral to specialist services not adjusted for at multivariable analysis due to 32.6% missingness which resulted in 57.9% listwise deletion.				

284

285 In the longitudinal sub-analysis that included both those that were inpatients and outpatients during  
286 acute COVID-19 (S4 Table), similar associations were observed as to the cross section sub-analysis (S2  
287 Table). The likelihood of presenting with long COVID significantly (p<0.001) declined, overall, across  
288 subsequent PAC-19 clinic visits (S4 Table). The presence of comorbidities were longitudinally associated  
289 with increased odds of long COVID by a factor of 1.67 (95% CI: 1.02-2.75). Hospitalized patients during  
290 acute COVID-19, vaccinated and male patients were associated with non-significant reduced likelihood  
291 of long COVID. Similarly, older age groups and presence of newly diagnosed medical conditions were  
292 associated with non-significant, however increased, odds of long COVID.

## 293 Discussion

294 Long COVID symptoms were common among patients presenting for care in specialized post-acute  
295 COVID-19 clinics in Zambia, which could represent potential substantial morbidity from COVID-19.  
296 Factors associated with long COVID in Zambia included severe COVID-19, hospital length of stay and  
297 presence of pre-existing comorbidities. Hospitalization was not significantly associated with long COVID  
298 while patients with limitations in daily activities that may have impacted on the patients' functional  
299 status were independently associated with long COVID. Longitudinally vaccination patients had  
300 indistinguishable likelihood of long COVID and so was sex and age.

301 A severe form of COVID-19 is known to increase the risk of an intense immune response that could lead  
302 to widespread inflammation [50]. The inflammatory response can persist post-acute infection and could  
303 have led to the immune system being dysregulated, leading to prolonged persistent symptoms and  
304 complications of COVID-19 in the patients. This could have led to observed association of severe COVID-  
305 19 long COVID as has been reported in other studies [35, 36, 51, 52].

306 Patients with longer hospital stays may have received intensive medical interventions and additional  
307 treatments. This could have potentially affected the immune response and the body's ability to recover  
308 from the acute COVID-19p, which in turn may have increased the likelihood of long COVID. Furthermore,

309 patients with pre-existing comorbidities may have been more susceptible to severe COVID-19 and may  
310 have been at higher risk of developing long COVID. This is consistent with what is reported by other  
311 studies on patients with longer hospitalization stay for acute COVID-19 or pre-existing comorbidities and  
312 their association to long COVID [52-54].

313 Patients referred to specialist services may have had residual organ damage from acute COVID-19 which  
314 may have required specialist care. This may have been closely related to the observed limitations in daily  
315 activities that may have impacted on the patients' functional status since acute COVID-19 as have been  
316 reported in a previous study [9]. Although this association was independently significant, we could not  
317 adjust for it at multivariable analysis due to missingness that resulted in listwise deletion of more than  
318 half the study sample. Furthermore, no feedback systems were in place to inform PAC-19 clinics of the  
319 outcome of specialist care of referred patients.

320 COVID-19 vaccines have been shown to be effective at preventing symptomatic SARS-CoV-2 infections  
321 and long COVID [55, 56]. In this study, however, vaccinated patients failed to show significant protective  
322 association between COVID vaccination and long COVID. A possible explanation for this finding might be  
323 the heterogeneity in vaccination status during the study since Zambia only began offering COVID-19  
324 vaccination in April 2021 (i.e., right before the delta wave and ~8 months after patients began  
325 presenting for care in PAC-19 clinics) [57]. For example, among the patients diagnosed with SARS-CoV-2  
326 during the wild type and beta dominant variants periods, prior to publicly available COVID-19  
327 vaccination in Zambia, only 1 patient ever reported being vaccinated.

328 Unlike pre-existing comorbidities, newly diagnosed medical conditions had a non-significant association  
329 with long COVID. Newly diagnosed medical conditions in COVID-19 patients may have been as a result of  
330 multiorgan effects or autoimmune conditions [3]. Fewer patients, overall, had newly diagnosed medical  
331 conditions which could explain the non-significant association. Sex and age were similarly not  
332 associated with long COVID which seem to suggest that factors associated with long COVID in Zambia  
333 were largely clinical as opposed to demographic.

334 With regards to recovery time from long COVID, most patients with long COVID had symptom resolution  
335 by the second month of follow up. Overall, we found that commonly reported long COVID symptoms in  
336 Zambia were similar to findings in other studies [35, 36, 38, 52]. However, symptoms like forgetfulness  
337 (commonly reported among long COVID patients) and change in sleep were less commonly reported in  
338 our study compared to previous reports [17, 20].



339 In both the cross-sectional and longitudinal analysis, inpatients compared to outpatient care during  
340 COVID-19 episode were found to be associated with indistinguishable likelihood of long COVID. One  
341 reason for this might be that those who were outpatient and attending PAC-19 clinics were a special  
342 subset of outpatients with COVID-19 (i.e., they were seeking out or were referred for follow-up care  
343 during acute COVID-19e). Furthermore, inpatients (the majority of whom had severe COVID-19) might  
344 have been more likely to be referred to PAC-19 clinic whereas those who were outpatient were likely  
345 self-referral to PAC-19 clinic meaning only those who really needed it (i.e., those with ongoing  
346 symptoms) were in this study.

347 The findings in this study are subject to several limitations. Firstly, only patients attending PAC-19 clinics  
348 were included in the study, so other patients with long COVID who sought care elsewhere (or didn't seek  
349 care) were not included. This potentially represents some form of selection bias within the study since  
350 other long COVID patients could have by-passed the PAC-19 clinic and presented directly to clinicians or  
351 specialist service at outpatient departments. Furthermore, PAC-19 clinics took time to scale-up  
352 throughout Zambia and some persons might still have faced difficulty accessing them. Overall, fewer  
353 than 1% of the over 344,000 confirmed COVID-19 cases in Zambia as of January 2023 presented for care  
354 in PAC-19 clinics.

355 Secondly, COVID-19 illness history (i.e., date of SARS-CoV-2 testing, hospitalization status, vaccination  
356 history, acute COVID-19 episode details, etc.) were self-reported by patients to clinicians which cannot  
357 rule out self-serving bias. Thirdly, the study utilized routinely collected clinical information from PAC-19  
358 clinics which had substantial missingness for some key variables such as vaccination status and referral  
359 to specialist services. Thus, these variables were not adjusted for at multivariable analyses so as to  
360 maintain sample size. And lastly, patients were not retested for SAR-CoV-2 infection at subsequent  
361 PAC-19 review visits and so the possibility of reinfection could not be ruled out.

## 362 **Conclusion**

363 Given the burden of COVID-19 in Zambia, the findings of a potentially substantial morbidity due to long  
364 COVID, and that yet few patients overall with COVID-19 had attended a PAC-19 clinic, scaling up PAC-19  
365 care services and integrating into routine clinical care could improve access by patients and further aid  
366 in understanding the true burden of long COVID in Zambia. This could be coupled with efforts to expand  
367 knowledge of long COVID among clinicians and the general population in Zambia. Scaling of vaccination,  
368 may likely, provide better outcomes not only for long COVID but also during acute SARS-CoV-2 infection.  
369 Improving data quality for routine clinical data, could possibly be achieved by utilizing the existing

370 electronic health record in Zambia (SmartCare) for all clinical encounters. Information sharing between  
371 referral care services and PAC-19 clinics could aid in understanding the outcome of long COVID among  
372 patients requiring specialist care.

373 **Disclaimer:** *The findings and conclusions in this report are those of the authors and do not necessarily*  
374 *represent the official position of the US Centers for Disease Control and Prevention (CDC) or the study*  
375 *funders.*

## 376 **Supporting information**

377 **S1 Fig:** Histogram of longitudinal PAC-19 clinic attendance (all visits) by time since COVID-19  
378 diagnosis, August 2020 January 2023

379  
380 **S1 Table:** Frequencies of pre-existing and newly diagnosed comorbidities of PAC-19 Clinic Patients  
381 in Zambia, Aug. 2020–Jan. 2023

382  
383 **S2 Table:** Factors associated with long COVID at first visit to PAC-19 clinic among acute COVID-19  
384 inpatients and outpatients in Zambia, August 2020 – January 2023 (N=1,359)

385  
386 **S3 Table:** Longitudinal Demographic and Clinical Characteristics of PAC-19 Clinic Patients in  
387 Zambia, Aug. 2020–Jan. 2023

388  
389 **S4 Table:** Longitudinal risk factors and association for long COVID among acute COVID-19  
390 hospitalized and non-hospitalized patients in Zambia, August 2020 – January 2023  
391 (N=548)

392

393

## 394 **References**

- 395 1. WHO. *International Health Regulations Emergency Committee on novel coronavirus in China.*  
396 2020 [cited 2022 12 May]; Available from: [https://www.who.int/news-](https://www.who.int/news-room/events/detail/2020/01/30/default-calendar/international-health-regulations-emergency-committee-on-novel-coronavirus-in-china)  
397 [room/events/detail/2020/01/30/default-calendar/international-health-regulations-emergency-](https://www.who.int/news-room/events/detail/2020/01/30/default-calendar/international-health-regulations-emergency-committee-on-novel-coronavirus-in-china)  
398 [committee-on-novel-coronavirus-in-china.](https://www.who.int/news-room/events/detail/2020/01/30/default-calendar/international-health-regulations-emergency-committee-on-novel-coronavirus-in-china)
- 399 2. WHO. *WHO Coronavirus (COVID-19) Dashboard.* 2023 [cited 2022 16 October]; Available from:  
400 [https://covid19.who.int/.](https://covid19.who.int/)
- 401 3. Raveendran, A.V., R. Jayadevan, and S. Sashidharan, *Long COVID: An overview.* *Diabetes Metab*  
402 *Syndr*, 2021. **15**(3): p. 869-875.
- 403 4. Klok, F.A., et al., *The Post-COVID-19 Functional Status scale: a tool to measure functional status*  
404 *over time after COVID-19.* *European Respiratory Journal*, 2020. **56**(1): p. 2001494.

- 405 5. Peghin, M., et al., *Post-COVID-19 symptoms 6 months after acute infection among hospitalized*  
406 *and non-hospitalized patients*. Clin Microbiol Infect, 2021. **27**(10): p. 1507-1513.
- 407 6. Soriano, J.B., et al., *A clinical case definition of post-COVID-19 condition by a Delphi consensus*.  
408 Lancet Infect Dis, 2022. **22**(4): p. e102-e107.
- 409 7. Venturelli, S., et al., *Surviving COVID-19 in Bergamo province: a post-acute outpatient re-*  
410 *evaluation*. Epidemiology and Infections, 2021. **149**: p. e32.
- 411 8. Ahmed, H., et al., *Long-term clinical outcomes in survivors of severe acute respiratory syndrome*  
412 *and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU*  
413 *admission: A systematic review and meta-analysis*. Journal of Rehabilitation of Medicine, 2020.  
414 **52**(5): p. jrm00063.
- 415 9. Hui, D.S., et al., *Impact of severe acute respiratory syndrome (SARS) on pulmonary function,*  
416 *functional capacity and quality of life in a cohort of survivors*. Thorax, 2005. **60**(5): p. 401-9.
- 417 10. Lam, M.H., et al., *Mental morbidities and chronic fatigue in severe acute respiratory syndrome*  
418 *survivors: long-term follow-up*. JAMA Internal Medicine, 2009. **169**(22): p. 2142-7.
- 419 11. Lee, S.H., et al., *Depression as a Mediator of Chronic Fatigue and Post-Traumatic Stress*  
420 *Symptoms in Middle East Respiratory Syndrome Survivors*. Psychiatry Investigation, 2019. **16**(1):  
421 p. 59-64.
- 422 12. Thaweethai, T., et al., *Development of a Definition of Postacute Sequelae of SARS-CoV-2*  
423 *Infection*. JAMA, 2023. **329**(22): p. 1934-1946.
- 424 13. Vahey, G.M., et al., *Symptom Profiles and Progression in Hospitalized and Nonhospitalized*  
425 *Patients with Coronavirus Disease, Colorado, USA, 2020*. Emerg Infect Dis, 2021. **27**(2): p. 385-  
426 395.
- 427 14. Nalbandian, A., et al., *Post-acute COVID-19 syndrome*. Nature Medicine, 2021. **27**(4): p. 601-615.
- 428 15. Chippa, V., A. Aleem, and F. Anjum, *Post Acute Coronavirus (COVID-19) Syndrome*. 2021:  
429 StatPearls Publishing, Treasure Island (FL).
- 430 16. Danesh, V., et al., *Symptom Clusters Seen in Adult COVID-19 Recovery Clinic Care Seekers*. J Gen  
431 Intern Med, 2023. **38**(2): p. 442-449.
- 432 17. Davis, H.E., et al., *Characterizing long COVID in an international cohort: 7 months of symptoms*  
433 *and their impact*. EClinicalMedicine, 2021. **38**: p. 101019.
- 434 18. WHO. *Post COVID-19 condition (Long COVID)*. 2022 [cited 2023 6 July]; Available from:  
435 <https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition>.
- 436 19. Carfi, A., R. Bernabei, and F. Landi, *Persistent Symptoms in Patients After Acute COVID-19*. JAMA,  
437 2020. **324**(6): p. 603-605.
- 438 20. Huang, C., et al., *6-month consequences of COVID-19 in patients discharged from hospital: a*  
439 *cohort study*. Lancet, 2021. **397**(10270): p. 220-232.
- 440 21. Tenforde, M.W., et al., *Symptom Duration and Risk Factors for Delayed Return to Usual Health*  
441 *Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States,*  
442 *March-June 2020*. MMWR Morb Mortal Wkly Rep, 2020. **69**(30): p. 993-998.
- 443 22. Ballering, A.V., et al., *Persistence of somatic symptoms after COVID-19 in the Netherlands: an*  
444 *observational cohort study*. Lancet, 2022. **400**(10350): p. 452-461.
- 445 23. Ayoubkhani, D., et al., *Risk of Long COVID in People Infected With Severe Acute Respiratory*  
446 *Syndrome Coronavirus 2 After 2 Doses of a Coronavirus Disease 2019 Vaccine: Community-*  
447 *Based, Matched Cohort Study*. Open Forum Infect Dis, 2022. **9**(9): p. ofac464.
- 448 24. Bull-Ottersen, L., et al., *Post-COVID Conditions Among Adult COVID-19 Survivors Aged 18-64*  
449 *and ≥65 Years — United States, March 2020–November 2021*. MMWR Morb Mortal Wkly Rep,  
450 2022. **71**(21): p. 713-7.
- 451 25. Ceban, F., et al., *Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic*  
452 *review and meta-analysis*. Brain Behav Immun, 2022. **101**: p. 93-135.

- 453 26. Xu, E., Y. Xie, and Z. Al-Aly, *Long-term neurologic outcomes of COVID-19*. *Nat Med*, 2022. **28**(11):  
454 p. 2406-2415.
- 455 27. Davis, H.E., et al., *Long COVID: major findings, mechanisms and recommendations*. *Nature*  
456 *Reviews Microbiology*, 2023.
- 457 28. Nyasulu, P.S., J.L. Tamuzi, and R.T. Erasmus, *Burden, causation, and particularities of Long COVID*  
458 *in African populations: A rapid systematic review*. *IJID Regions*, 2023. **8**: p. 137-144.
- 459 29. Antonelli, M., et al., *Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in*  
460 *UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-*  
461 *control study*. *Lancet Infect Dis*, 2022. **22**(1): p. 43-55.
- 462 30. Morello, R., et al., *Risk factors for post-COVID-19 condition (Long Covid) in children: a*  
463 *prospective cohort study*. *eClinicalMedicine*, 2023. **59**: p. 101961.
- 464 31. Tsampasian, V., et al., *Risk Factors Associated With Post-COVID-19 Condition: A Systematic*  
465 *Review and Meta-analysis*. *JAMA Internal Medicine*, 2023. **183**(6): p. 566-580.
- 466 32. Frallonardo, L., et al., *Incidence and burden of long COVID in Africa: a systematic review and*  
467 *meta-analysis*. *Scientific Reports*, 2023. **13**(1): p. 21482.
- 468 33. Osikomaiya, B., et al., *'Long COVID': persistent COVID-19 symptoms in survivors managed in*  
469 *Lagos State, Nigeria*. *BMC Infectious Diseases*, 2021. **21**(1): p. 304.
- 470 34. Müller, S.A., et al., *Prevalence and risk factors for long COVID and post-COVID-19 condition in*  
471 *Africa: a systematic review*. *Lancet Glob Health*, 2023. **11**(11): p. e1713-e1724.
- 472 35. Osikomaiya, B., et al., *'Long COVID': persistent COVID-19 symptoms in survivors managed in*  
473 *Lagos State, Nigeria*. *BMC Infect Dis*, 2021. **21**(1): p. 304.
- 474 36. Dryden, M., et al., *Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in*  
475 *South Africa: a prospective cohort study*. *Lancet Glob Health*, 2022. **10**(9): p. e1247-e1256.
- 476 37. Moyo, E., et al., *Risk factors and clinical presentations of long COVID in Africa: A scoping review*.  
477 *Journal of Infection and Public Health*, 2023. **16**(12): p. 1982-1988.
- 478 38. Zulu, J.E., et al., *Two-month follow-up of persons with SARS-CoV-2 infection-Zambia, September*  
479 *2020: a cohort study*. *Pan Afr Med J*, 2022. **41**: p. 26.
- 480 39. Mulenga, L.B., et al., *Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-*  
481 *sectional cluster sample survey*. *Lancet Glob Health*, 2021. **9**(6): p. e773-e781.
- 482 40. Sheppard, R.J., et al., *Using mortuary and burial data to place COVID-19 in Lusaka, Zambia*  
483 *within a global context*. *Nat Commun*, 2023. **14**(1): p. 3840.
- 484 41. Gill, C.J., et al., *What is the prevalence of COVID-19 detection by PCR among deceased*  
485 *individuals in Lusaka, Zambia? A postmortem surveillance study*. *BMJ Open*, 2022. **12**(12): p.  
486 e066763.
- 487 42. Heilmann, E., et al., *SARS-COV-2 seroprevalence trend among pregnant women in Zambia, 2021-*  
488 *2022, in Conference on Retroviruses and Opportunistic Infections (CROI)*. 2023: Seattle,  
489 Washington.
- 490 43. Mumba, T.K., et al., *Seroprevalence survey of SARS-CoV-2, community behaviors, and practices in*  
491 *Kansanshi and Kalumbila mining towns*. *Frontiers in Public Health*, 2023. **11**.
- 492 44. Shanaube, K., et al., *SARS-CoV-2 seroprevalence and associated risk factors in periurban Zambia:*  
493 *a population-based study*. *Int J Infect Dis*, 2022. **118**: p. 256-263.
- 494 45. Lewis, H.C., et al., *SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of*  
495 *standardised seroprevalence studies, from January 2020 to December 2021*. *BMJ Glob Health*,  
496 2022. **7**(8).
- 497 46. Ministry of Health (Zambia). *Clinical Guidance for Management of Patients with Coronavirus*  
498 *Disease 2019 (COVID-19)*. 2020 [cited 2023 12 August]; Available from:  
499 [https://www.moh.gov.zm/?wpfb\\_dl=181](https://www.moh.gov.zm/?wpfb_dl=181).

- 500 47. Ministry of Health, *Clinical and Operational Guidelines for the Management of Post-Acute Covid-*  
501 *19 (PAC-19) Patients in Zambia*, in *Post-Acute COVID-19 Clinical and Operational Guidelines*.  
502 2022, Ministry of Health (Zambia): Lusaka.
- 503 48. GISAID. *EpiCov*. 2023 [cited 2023 12 August]; Available from:  
504 <https://www.epicov.org/epi3/frontend#24d000>.
- 505 49. Charan, J. and T. Biswas, *How to calculate sample size for different study designs in medical*  
506 *research?* Indian J Psychol Med, 2013. **35**(2): p. 121-6.
- 507 50. Wong, R.S.Y., *Inflammation in COVID-19: from pathogenesis to treatment*. Int J Clin Exp Pathol,  
508 2021. **14**(7): p. 831-844.
- 509 51. Zhang, H.P., et al., *Recent developments in the immunopathology of COVID-19*. Allergy, 2023.  
510 **78**(2): p. 369-388.
- 511 52. Fernández-de-las-Peñas, C., et al., *Prevalence of post-COVID-19 symptoms in hospitalized and*  
512 *non-hospitalized COVID-19 survivors: A systematic review and meta-analysis*. European Journal  
513 of Internal Medicine, 2021. **92**: p. 55-70.
- 514 53. Cirulli, E.T., et al., *Long-term COVID-19 symptoms in a large unselected population*. medRxiv,  
515 2020: p. 2020.10.07.20208702.
- 516 54. Asadi-Pooya, A.A., et al., *Risk Factors Associated with Long COVID Syndrome: A Retrospective*  
517 *Study*. Iran J Med Sci, 2021. **46**(6): p. 428-436.
- 518 55. Rane, M.S., et al., *Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic*  
519 *SARS-CoV-2 infections in an urgent care setting*. Vaccine, 2023. **41**(4): p. 989-998.
- 520 56. Britton, A., et al., *Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection*  
521 *by Time Since Vaccination and Delta Variant Predominance*. Jama, 2022. **327**(11): p. 1032-1041.
- 522 57. Chanda, D., et al., *COVID-19 Vaccine Effectiveness Against Progression to In-Hospital Mortality in*  
523 *Zambia, 2021-2022*. Open Forum Infect Dis, 2022. **9**(9): p. ofac469.

524

525